260 related articles for article (PubMed ID: 18785547)
41. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group.
Schmitz FJ; Verhoef J; Fluit AC
Int J Antimicrob Agents; 1999 Aug; 12(4):311-7. PubMed ID: 10493607
[TBL] [Abstract][Full Text] [Related]
42. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Jones RN; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):49-56. PubMed ID: 8026157
[TBL] [Abstract][Full Text] [Related]
43. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
44. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
Fedler KA; Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
[TBL] [Abstract][Full Text] [Related]
45. Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.
Cormican MG; Jones RN
J Clin Microbiol; 1995 Jan; 33(1):215-6. PubMed ID: 7699045
[TBL] [Abstract][Full Text] [Related]
46. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Sirvent E; Ruiz M; Rodríguez JC; Royo G
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
[TBL] [Abstract][Full Text] [Related]
48. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
Yamane N; Jones RN; Frei R; Hoban DJ; Pignatari AC; Marco F
J Chemother; 1994 Apr; 6(2):83-91. PubMed ID: 8077990
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
50. Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.
Hoshi S; Kikuchi K; Sasaki T; Sotozono C; Kinoshita S; Hiramatsu K
Antimicrob Agents Chemother; 2008 Aug; 52(8):2970-3. PubMed ID: 18490505
[TBL] [Abstract][Full Text] [Related]
51. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
52. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
[TBL] [Abstract][Full Text] [Related]
53. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Esel D; Doganay M; Sumerkan B
Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
[TBL] [Abstract][Full Text] [Related]
54. [Etiological analysis on bacterial endophthalmitis].
Ren Z; Wang ZQ; Li R; Luo SY; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2007 Dec; 43(12):1106-9. PubMed ID: 18331681
[TBL] [Abstract][Full Text] [Related]
55. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Ebisu H; Kishii R; Takei M; Fukuda H
J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
[TBL] [Abstract][Full Text] [Related]
56. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
Rolston KV; Kontoyiannis DP; Yadegarynia D; Raad II
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
[TBL] [Abstract][Full Text] [Related]
57. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
58. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
[TBL] [Abstract][Full Text] [Related]
59. Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
Di Bonaventura G; D'Antonio D; Catamo G; D'Ercole S; Piccolomini R
Chemotherapy; 2002 Jul; 48(3):134-7. PubMed ID: 12138329
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
